Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+)
Michael C. Heinrich(VA Portland Health Care System), Jonathan A. Fletcher(Harvard University), Christopher L. Corless(Oregon Health & Science University), Donna Hollis(University of North Carolina at Chapel Hill), Jennifer Shoemaker(Dartmouth–Hitchcock Medical Center), George D. Demetri(American Society of Clinical Oncology), Monica M. Bertagnolli(National Institutes of Health)
Cited by 64
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
|Journal of Clinical Oncology|2010|840
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716